Literature DB >> 29410283

New insights into the Vav1 activation cycle in lymphocytes.

María Barreira1, Sonia Rodríguez-Fdez1, Xosé R Bustelo2.   

Abstract

Vav1 is a hematopoietic-specific Rho GDP/GTP exchange factor and signaling adaptor. Although these activities are known to be stimulated by direct Vav1 phosphorylation, little information still exists regarding the regulatory layers that influence the overall Vav1 activation cycle. Using a collection of cell models and activation-mimetic Vav1 mutants, we show here that the dephosphorylated state of Vav1 in nonstimulated T cells requires the presence of a noncatalytic, phospholipase Cγ1-Slp76-mediated inhibitory pathway. Upon T cell stimulation, Vav1 becomes rapidly phosphorylated via the engagement of Lck and, to a much lesser extent, other Src family kinases and Zap70. In this process, Lck, Zap70 and the adaptor protein Lat contribute differently to the dynamics and amplitude of the Vav1 phosphorylated pool. Consistent with a multiphosphosite activation mechanism, the optimal stimulation of Vav1 can only be recapitulated by the combination of several activation-mimetic phosphosite mutants. The analysis of these mutants has also unveiled the presence of different Vav1 signaling competent states that are influenced by phosphosites present in the N- and C-terminal domains of the protein.
Copyright © 2018 Elsevier Inc. All rights reserved.

Entities:  

Keywords:  B cell receptor; Conformational states; Exchange factors; JNK; Lat; Lck; Lymphocytes; NFAT; Phospholipase Cγ; Phosphosites; Protein tyrosine phosphatases; Rac1; Signaling diversification; Slp76; Src family; T cell receptor; Zap70

Mesh:

Substances:

Year:  2018        PMID: 29410283     DOI: 10.1016/j.cellsig.2018.01.026

Source DB:  PubMed          Journal:  Cell Signal        ISSN: 0898-6568            Impact factor:   4.315


  8 in total

1.  Vav2 lacks Ca2+ entry-promoting scaffolding functions unique to Vav1 and inhibits T cell activation via Cdc42.

Authors:  Michael A Fray; John C Charpentier; Nicholas R Sylvain; Maria-Cristina Seminario; Stephen C Bunnell
Journal:  J Cell Sci       Date:  2020-03-13       Impact factor: 5.285

2.  A novel role for an old target: CD45 for breast cancer immunotherapy.

Authors:  Annat Raiter; Oran Zlotnik; Julia Lipovetsky; Shany Mugami; Shira Dar; Ido Lubin; Eran Sharon; Cyrille J Cohen; Rinat Yerushalmi
Journal:  Oncoimmunology       Date:  2021-05-25       Impact factor: 8.110

3.  VAV1 Gene Polymorphisms in Patients with Rheumatoid Arthritis.

Authors:  Andrzej Pawlik; Damian Malinowski; Agnieszka Paradowska-Gorycka; Krzysztof Safranow; Violetta Dziedziejko
Journal:  Int J Environ Res Public Health       Date:  2020-05-05       Impact factor: 3.390

Review 4.  The Vav GEF Family: An Evolutionary and Functional Perspective.

Authors:  Sonia Rodríguez-Fdez; Xosé R Bustelo
Journal:  Cells       Date:  2019-05-16       Impact factor: 6.600

5.  Ehrlichia chaffeensis Uses an Invasin To Suppress Reactive Oxygen Species Generation by Macrophages via CD147-Dependent Inhibition of Vav1 To Block Rac1 Activation.

Authors:  Omid Teymournejad; Yasuko Rikihisa
Journal:  mBio       Date:  2020-04-21       Impact factor: 7.867

6.  Cancer-associated mutations in VAV1 trigger variegated signaling outputs and T-cell lymphomagenesis.

Authors:  Javier Robles-Valero; Lucía Fernández-Nevado; L Francisco Lorenzo-Martín; Myriam Cuadrado; Isabel Fernández-Pisonero; Sonia Rodríguez-Fdez; Elsa N Astorga-Simón; Antonio Abad; Rubén Caloto; Xosé R Bustelo
Journal:  EMBO J       Date:  2021-10-07       Impact factor: 11.598

7.  Lysine Acetylation Reshapes the Downstream Signaling Landscape of Vav1 in Lymphocytes.

Authors:  Sonia Rodríguez-Fdez; Lucía Fernández-Nevado; L Francisco Lorenzo-Martín; Xosé R Bustelo
Journal:  Cells       Date:  2020-03-04       Impact factor: 6.600

8.  Phosphatidylinositol Monophosphates Regulate Optimal Vav1 Signaling Output.

Authors:  Sonia Rodríguez-Fdez; Carmen Citterio; L Francisco Lorenzo-Martín; Jesús Baltanás-Copado; Clara Llorente-González; Senena Corbalán-García; Miguel Vicente-Manzanares; Xosé R Bustelo
Journal:  Cells       Date:  2019-12-16       Impact factor: 6.600

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.